# Safety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma

> **NCT06021678** · PHASE1,PHASE2 · RECRUITING · sponsor: **Guangzhou Excelmab Inc.** · enrollment: 415 (estimated)

## Conditions studied

- CD20-positive Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** EX103 injection

## Key facts

- **NCT ID:** NCT06021678
- **Lead sponsor:** Guangzhou Excelmab Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-11-12
- **Primary completion:** 2025-10
- **Final completion:** 2025-12
- **Target enrollment:** 415 (ESTIMATED)
- **Last updated:** 2025-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06021678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06021678, "Safety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06021678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*